The production and supply in Canada are designed to address the growing need for no-carrier-added Lutetium-177 (n.c.a. Lu-177) in North America
Tislelizumab is now approved in nine indications in China
Company hires life science veteran Jessica Cao to join management team
We have grown from $10 billion to $80 billion. India is not too far from reaching the league of top-10 countries in Biotech's global ecosystem”
Healthcare is timely and personal – and its delivery should be too
Based on a post hoc analysis, fewer required respiratory interventions
Steinberg brings nearly three decades of experience in biopharmaceutical equity research to Prolacta's executive team.
This MoU will further strengthen relations between India and the USA within the framework of international scientific and technological cooperation in fields of mutual interest.
The drug will be manufactured at the group’s topical facility at Ahmedabad
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
Subscribe To Our Newsletter & Stay Updated
